Cargando…

Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma

A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin’s lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfaifi, Abdullah, Refai, Mohammed Y., Alsaadi, Mohammed, Bahashwan, Salem, Malhan, Hafiz, Al-Kahiry, Waiel, Dammag, Enas, Ageel, Ageel, Mahzary, Amjed, Albiheyri, Raed, Almehdar, Hussein, Qadri, Ishtiaq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000528/
https://www.ncbi.nlm.nih.gov/pubmed/36900005
http://dx.doi.org/10.3390/diagnostics13050861
_version_ 1784903899590688768
author Alfaifi, Abdullah
Refai, Mohammed Y.
Alsaadi, Mohammed
Bahashwan, Salem
Malhan, Hafiz
Al-Kahiry, Waiel
Dammag, Enas
Ageel, Ageel
Mahzary, Amjed
Albiheyri, Raed
Almehdar, Hussein
Qadri, Ishtiaq
author_facet Alfaifi, Abdullah
Refai, Mohammed Y.
Alsaadi, Mohammed
Bahashwan, Salem
Malhan, Hafiz
Al-Kahiry, Waiel
Dammag, Enas
Ageel, Ageel
Mahzary, Amjed
Albiheyri, Raed
Almehdar, Hussein
Qadri, Ishtiaq
author_sort Alfaifi, Abdullah
collection PubMed
description A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin’s lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin’s lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called “metabolomics.” A patient’s phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin’s lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin’s lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin’s lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin’s lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches.
format Online
Article
Text
id pubmed-10000528
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100005282023-03-11 Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma Alfaifi, Abdullah Refai, Mohammed Y. Alsaadi, Mohammed Bahashwan, Salem Malhan, Hafiz Al-Kahiry, Waiel Dammag, Enas Ageel, Ageel Mahzary, Amjed Albiheyri, Raed Almehdar, Hussein Qadri, Ishtiaq Diagnostics (Basel) Review A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin’s lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin’s lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called “metabolomics.” A patient’s phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin’s lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin’s lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin’s lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin’s lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches. MDPI 2023-02-23 /pmc/articles/PMC10000528/ /pubmed/36900005 http://dx.doi.org/10.3390/diagnostics13050861 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alfaifi, Abdullah
Refai, Mohammed Y.
Alsaadi, Mohammed
Bahashwan, Salem
Malhan, Hafiz
Al-Kahiry, Waiel
Dammag, Enas
Ageel, Ageel
Mahzary, Amjed
Albiheyri, Raed
Almehdar, Hussein
Qadri, Ishtiaq
Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
title Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
title_full Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
title_fullStr Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
title_full_unstemmed Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
title_short Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
title_sort metabolomics: a new era in the diagnosis or prognosis of b-cell non-hodgkin’s lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000528/
https://www.ncbi.nlm.nih.gov/pubmed/36900005
http://dx.doi.org/10.3390/diagnostics13050861
work_keys_str_mv AT alfaifiabdullah metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT refaimohammedy metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT alsaadimohammed metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT bahashwansalem metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT malhanhafiz metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT alkahirywaiel metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT dammagenas metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT ageelageel metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT mahzaryamjed metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT albiheyriraed metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT almehdarhussein metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma
AT qadriishtiaq metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma